Humacyte announces publication of results on ATEV

Humacyte (HUMA) announced the publication of clinical results evaluating the efficacy and safety of the acellular tissue engineered vessel, ATEV, in the repair of extremity civilian and military injuries in JAMA Surgery, an American Medical Association peer-reviewed journal. The publication “Bioengineered Human Arteries for the Repair of Vascular Injuries” describes two clinical studies in which the ATEV demonstrated benefits in terms of patency (blood flow), limb salvage, and infection resistance compared to synthetic graft benchmarks in the treatment of acute vascular injuries of the extremities. The JAMA Surgery publication described the results of two studies in which the ATEV was evaluated in patients with extremity vascular trauma. In summary, researchers concluded that the 30-day outcomes in civilian and military trauma patients indicate superior secondary patency, limb salvage, and resistance to infection of the ATEV conduit compared to synthetic grafts.